OverviewSuggest Edit
Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. The Company bases its approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.
| Type | Public | |
| Founded | 2013 | |
| HQ | Stamford, US | Map |
| Website | loxooncology.com |
Recent NewsAll News
- Lilly Completes Acquisition of Loxo Oncology
- Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
- Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
- WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders
Key People/Management at Loxo Oncology
Josh Bilenker
Founder, President & CEO
Nisha Nanda
VP of Development Strategy
Jacob Van Naarden
Chief Business Officer
Jennifer Burstein
VP of Finance
Report incorrect company information
Loxo Oncology Office Locations
Loxo Oncology has offices in Stamford and South San Francisco
Stamford, US (HQ)
281 Tresser Blvd, 14th Floor
South San Francisco, US
400 Oyster Point Blvd #520
Report incorrect company information
Loxo Oncology Financials and Metrics
Loxo Oncology Revenue
| USD | |
|---|---|
Net income (Q2, 2018) | (15.3m) |
EBIT (Q2, 2018) | (20.5m) |
Market capitalization (15-Feb-2019) | 7.2b |
Closing stock price (15-Feb-2019) | 234.7 |
Cash (30-Jun-2018) | 147.7m |
Loxo Oncology's current market capitalization is $7.2 b.
- Source: SEC Filings
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 2.4m | 2.6m | 3.4m | 3.8m | 3.7m | 4.8m | 6.5m | 9.7m | 12.2m | 27.9m |
R&D expense | 2.8m | 3.4m | 8.4m | 12.3m | 14.2m | 20.2m | 24.4m | 64.8m | 32.0m | 73.5m |
Operating expense total | 5.2m | 5.9m | 11.8m | 16.1m | 17.9m | 24.9m | 30.9m | 74.4m | 44.2m | 101.5m |
EBIT | (5.8m) | (20.5m) |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 118.6m | 36.6m | 34.4m | 51.9m | 48.5m | 260.3m | 80.4m | 103.8m | 147.7m |
Current Assets | 120.0m | 103.2m | 96.4m | 159.6m | 244.4m | 471.4m | 376.6m | 720.6m | 676.7m |
PP&E | 13.0k | 78.0k | 74.0k | 269.0k | 328.0k | 364.0k | 566.0k | 1.6m | 3.3m |
Total Assets | 120.1m | 103.3m | 96.7m | 161.5m | 249.4m | 472.4m | 411.5m | 748.6m | 716.5m |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.1m) | (8.8m) | (11.6m) | (15.9m) | (17.7m) | (24.5m) | (54.9m) | (128.2m) | (3.6m) | (15.3m) | ||
Depreciation and Amortization | 21.0k | 48.0k | 80.0k | 80.0k | 186.0k | |||||||
Accounts Payable | 207.0k | 285.0k | 415.0k | 731.0k | 758.0k | 677.0k | 1.0m | 192.0k | 1.1m | 768.0k | 1.8m | 793.0k |
Cash From Operating Activities | (26.7m) | (50.5m) | (113.4m) | 109.8m | 74.8m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.8 x |
Report incorrect company information
Loxo Oncology Online and Social Media Presence
Report incorrect company information
Loxo Oncology News and Updates
February 15, 2019
Lilly Completes Acquisition of Loxo Oncology
INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of ...
February 06, 2019
Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
INDIANAPOLIS, Feb. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018. $ in millions, except per share data Fourth Quarter % Full Year % 2018 2017 Change 2018 2017 Change Revenue $ 6,438.6 $ 6,160.7 5% $ ...
February 01, 2019
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the…
January 08, 2019
WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders
NEW YORK, Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" or the "Company") (NASDAQ: LOXO) in connection with the proposed acquisition of the Company by Eli...
January 07, 2019
UPDATE 5-Lilly makes $8 bln bet on drugs for rare cancers with Loxo Oncology buy
Eli Lilly said on Monday it will
buy Loxo Oncology Inc for $8 billion, an expensive bet
on a pipeline of cancer drugs that target rare genetic mutations
and the biggest acquisition in the drugmaker's 143-year history.
January 07, 2019
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Loxo Oncology, Inc.
NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc. (NASDAQ: LOXO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders ...
Report incorrect company information
Loxo Oncology Frequently Asked Questions
When was Loxo Oncology founded?
Loxo Oncology was founded in 2013.
Who are Loxo Oncology key executives?
Loxo Oncology's key executives are Josh Bilenker, Nisha Nanda and Jacob Van Naarden.
How many employees does Loxo Oncology have?
Loxo Oncology has 59 employees.
Who are Loxo Oncology competitors?
Competitors of Loxo Oncology include LGC Biosearch Technologies, Fate Therapeutics and Parexel International.
Where is Loxo Oncology headquarters?
Loxo Oncology headquarters is located at 281 Tresser Blvd, 14th Floor, Stamford.
Where are Loxo Oncology offices?
Loxo Oncology has offices in Stamford and South San Francisco.
How many offices does Loxo Oncology have?
Loxo Oncology has 2 offices.